Thu, Aug 21, 2014, 11:25 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

SpendSmart Networks, Inc. Message Board

e.wickadp 1 post  |  Last Activity: Jun 29, 2014 11:15 AM Member since: Jan 5, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • 3 Potentially Game-Changing Investigational Breast Cancer Drugs That May Soon Be Available

    NeuVax
    Sometimes the biggest battles aren't fought against tumor proliferation, but are instead intended to keep cancer from reforming. Galena Biopharma's (NASDAQ: GALE ) primary mission with NeuVax, an adjuvant therapy given to patients that have received chemotherapy, is to keep breast cancer from coming back.

    Galena's vaccine is part of a new line of investigational cancer therapies known as cancer immunotherapies. Drugs in this class work by enhancing or teaching the body's immune system to recognize specific cancer cells and eradicate them. NeuVax stimulates CD8+ cytotoxic T lymphocytes which are activated and subsequently seek out and destroy HER2-expressing cancer cells.

    In late 2012 Galena released the final results of a five-year phase 2 study involving NeuVax, with the SN-33 (node-positive) study showing that just 5.6% of patients given NeuVax had a recurrence. By comparison, just over one-in-four patients had their cancer return in the control arm. Overall, NeuVax resulted in a cancer recurrence reduction of 78.4%!

    Yet the greatest aspect of NeuVax might be patient convenience. No patient enjoys receiving cancer therapy, but over the course of three years patients will only receive a total of 11 NeuVax intradermal injections. If its phase 2 results carry over into its ongoing PRESENT phase 3 trial, then it could allow for greater peace of mind for patients who'll spend less time receiving medical care and more time enjoying life.

    One factor to consider here, though, is that Galena is a relatively small company, and historically small biopharmaceuticals have had little success in getting cancer therapies approved by the FDA. The data so far has done the talking, but it's something to consider as a possible investor in this potentially game-changing investigational vaccine. Interim data on NeuVax's PRESENT study should be out sometime next year.

    Sentiment: Strong Buy

SSPC
1.25-0.05(-3.85%)Aug 21 2:04 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.